Gordon Sun to Cost-Benefit Analysis
This is a "connection" page, showing publications Gordon Sun has written about Cost-Benefit Analysis.
Connection Strength
0.251
-
Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States. Am J Clin Oncol. 2018 Jan; 41(1):65-72.
Score: 0.142
-
Pediatric deep space neck infections in U.S. children, 2000-2009. Int J Pediatr Otorhinolaryngol. 2014 May; 78(5):832-6.
Score: 0.109